Analog vs Human Insulin Tied to Lower Death Risk in the Hemodialysis Population
Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death.
Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death.
Growth differentiation factor-15 predicts major bleeding, major adverse cardiac events, and mortality in patients on hemodialysis.
Predicted probability of success of future larger trial was 25% and 14% for <140 and <160 mm Hg, respectively
Risk increased for recurrent MI, ischemic stroke, or death with suboptimal adherence through 8 years after MI
Early use tied to better postoperative functional outcomes without hemorrhagic transformation risk
The 5-year number needed to treat to prevent the primary cardiovascular outcome 25 in patients with lower eGFR compared with 67 among those with normal eGFR.
After 1 year of aggressive medical management, diastolic BP and physical activity scores no longer differ for Blacks, non-Blacks
Researchers identified patterns of smoking habits after a cancer diagnosis and the associated risks of cardiovascular events.
A study was conducted to determine the effect of microvascular disease on cardiovascular morbidity and mortality in patients with type 2 diabetes.
Increase seen in in-hospital mortality and 7 perioperative complications for adults undergoing major elective inpatient surgery